These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29700687)

  • 1. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.
    Hochmair M
    Target Oncol; 2018 Jun; 13(3):269-285. PubMed ID: 29700687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Ahluwalia MS; Becker K; Levy BP
    Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
    Hoffknecht P; Tufman A; Wehler T; Pelzer T; Wiewrodt R; Schütz M; Serke M; Stöhlmacher-Williams J; Märten A; Maria Huber R; Dickgreber NJ;
    J Thorac Oncol; 2015 Jan; 10(1):156-63. PubMed ID: 25247337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M; Singhal MK; Kamle MS
    Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.
    Popat S; Ahn MJ; Ekman S; Leighl NB; Ramalingam SS; Reungwetwattana T; Siva S; Tsuboi M; Wu YL; Yang JC
    Target Oncol; 2023 Jan; 18(1):9-24. PubMed ID: 36652172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
    Zhou Y; Wang B; Qu J; Yu F; Zhao Y; Li S; Zeng Y; Yang X; Chu L; Chu X; Li Y; Zou L; Guo T; Ye L; Liang F; Wang S; Liu Q; Ni J; Zhu Z
    Lung Cancer; 2020 Dec; 150():178-185. PubMed ID: 33186860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.
    Batra U; Lokeshwar N; Gupta S; Shirsath P
    Indian J Cancer; 2017 Dec; 54(Supplement):S37-S44. PubMed ID: 29292707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
    Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
    How J; Mann J; Laczniak AN; Baggstrom MQ
    Clin Lung Cancer; 2017 Jul; 18(4):354-363. PubMed ID: 28245967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.
    Kim DH; Choi YJ; Sung KJ; Yoo SA; Sung YH; Kim JK; Choi CM; Yun M; Lee EY; Jin YS; Cook S; Rho JK; Lee JC
    Mol Oncol; 2018 Dec; 12(12):2182-2190. PubMed ID: 30350450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
    BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness.
    Hirsh V; Singh J
    Am J Health Syst Pharm; 2020 Sep; 77(18):1466-1476. PubMed ID: 32885829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.
    Kim HR; Jo H; Kim H; Hong J; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ
    Cancer Res Treat; 2023 Jan; 55(1):344-349. PubMed ID: 35344648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    Li MX; He H; Ruan ZH; Zhu YX; Li RQ; He X; Lan BH; Zhang ZM; Liu GD; Xiao HL; Wu Y; Zhu B; Wang G; Yang ZZ
    BMC Cancer; 2017 Apr; 17(1):245. PubMed ID: 28376735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.